Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Epic Bio Completes $55 Million Funding Led by HK’s Horizon to Modify Gene Expression

publication date: Jul 14, 2022

Epic Bio of South San Francisco completed a $55 million Series A round to develop ultracompact therapies that modulate gene expression in vivo. The funding was led by Hong Kong’s Horizon Ventures, which has backed several gene editing companies. Epic has developed the GEMS (Gene Expression Modulation System) platform to turn gene expression on and off. It also licensed rights to the ultracompact DNA-binding protein CasMINI for human use. CasMINI is the smallest Cas protein created to date, developed in the Stanford lab of Stanley Qi, PhD, the founder of Epic. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital